• Warren Wen, Steve Sitar, Shau Yu Lynch, Ellie He, and Steven R Ripa.
• Medical Research, Purdue Pharma L.P. , One Stamford Forum, Stamford, CT 06901 , USA +1 203 588 7631 ; +1 203 588 7423 ; Warren.Wen@pharma.com.
• Expert Opin Pharmacother. 2015 Jan 1;16(11):1593-606.

ObjectivesThis multicenter, randomized, double-blind, placebo-controlled study with an enriched enrollment, randomized withdrawal design was conducted to evaluate the analgesic efficacy and safety of single-entity, once-daily hydrocodone 20 to 120 mg tablets (HYD) in opioid-naive and opioid-experienced patients with uncontrolled moderate to severe chronic low back pain (CLBP).Research Design And MethodsThe primary endpoint was week 12 pain intensity scores (11-point scale, 0 = no pain) using a mixed effect model with repeated measures incorporating a pattern mixture model framework. Responder analysis was a secondary endpoint. Safety was assessed.ResultsOut of 905 patients who were treated with HYD during the open-label titration period, 588 (65%) were randomized to continue to receive HYD (n = 296, 20 - 120 mg taken once daily, average daily dose 57 mg) or a matching placebo (n = 292). HYD demonstrated superior pain reduction (p = 0.0016); this result was supported by sensitivity analyses using different approaches to handling missing data. Proportions of patients achieving ≥ 30 and ≥ 50% improvement in pain from screening to week 12 also favored HYD (p = 0.0033 and 0.0225, respectively). HYD was generally well tolerated.ConclusionsHYD was shown to be an efficacious treatment for CLBP in this study. There were no new or unexpected safety concerns detected.

22 keywords...

hide…